Action ARTL ARTELO BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Artelo Biosciences, Inc.

Actions

ARTL

US04301G5080

Temps Différé Nasdaq
Autres places de cotation
 17:19:22 26/06/2024 		Varia. 5j. Varia. 1 janv.
1,346 USD -2,50 % Graphique intraday de Artelo Biosciences, Inc. +6,79 % -3,89 %
13/05 Artelo Biosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
23/04 Transcript : Artelo Biosciences, Inc. - Special Call

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
Top Premarket Gainers
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ARTL
  4. Actualités Artelo Biosciences, Inc.
  5. Autres langues